Management of Antimicrobial Resistance in Urinary Tract Infections

Urinary tract infections (UTIs) remain a leading cause of bacterial morbidity, particularly among women, and the global rise in antimicrobial resistance poses a critical challenge to effective management. The cornerstone of contemporary practice involves early and accurate diagnosis, incorporating point-of-care dipstick testing and selective urine culture to guide therapy. Empiric antibiotic selection is increasingly informed by local and regional resistance data, with nitrofurantoin and fosfomycin favoured for uncomplicated lower UTIs owing to their retained activity against common uropathogens. For complicated or recurrent cases, longer-acting agents and combination regimens are considered, alongside catheter management and correction of anatomical abnormalities. Antimicrobial stewardship programmes have been pivotal in reducing unnecessary broad-spectrum antibiotic use, while surveillance networks monitor emerging resistance mechanisms such as extended-spectrum β-lactamases. Novel approaches under investigation include pathogen-directed therapy guided by rapid molecular diagnostics, therapeutic vaccines, bacteriophage preparations and the development of new oral antibiotics. Integration of pharmacokinetic modelling, precision dosing in patients with renal impairment and adherence to guideline-driven algorithms are essential to curtail the spread of multidrug-resistant strains and preserve treatment efficacy.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Antimicrobial Resistance in Urinary Tract Infections publication trend

The graph below shows the total number of articles in management of antimicrobial resistance in urinary tract infections across all publications each year (not limited to Nature Index journals).

Technical terms

Antimicrobial stewardship: Coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents by promoting the selection of optimal drug regimens.

Extended-spectrum β-lactamase (ESBL): Enzymes produced by certain bacteria that confer resistance to penicillins, cephalosporins and aztreonam, complicating standard antibiotic therapy.

Empiric therapy: Initiation of antibiotic treatment based on the most likely pathogens and local resistance patterns before specific microbiological results are available.

Minimum inhibitory concentration (MIC): The lowest concentration of an antimicrobial that prevents visible growth of a microorganism in vitro, used to gauge susceptibility.

Uropathogen: Any microorganism that is capable of causing urinary tract infection, most commonly Escherichia coli but also including Klebsiella, Proteus and Staphylococcus species.

References

1. Development of a Physiologically Based Pharmacokinetic Model for Nitrofurantoin in Rabbits, Rats, and Humans. Pharmaceutics (2023).
2. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Frontiers in Cellular and Infection Microbiology (2023).
3. Artificial Intelligence Can Guide Antibiotic Choice in Recurrent UTIs and Become an Important Aid to Improve Antimicrobial Stewardship. Antibiotics (2023).
4. Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020). Antimicrobial Agents and Chemotherapy (2023).
5. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. International Journal of Antimicrobial Agents (2022).